Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Flucelvax vs Agrippal in Healthy Adults
NCT00630331Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2007
- Primary completion
- Jul 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 3 trial of Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated) in influenza, sponsored by Novartis. Started Oct 2007; status: completed.
02
Drugs
Influenza B virus B/Utah/9/2014 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00630331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630331.